Fixed drug eruption after Pfizer-BioNTech COVID-19 vaccine: A case report.

Lellig, Elodie; Mouton-Faivre, Claudie; Abs, Diane; Bursztejn, Anne-Claire

Lellig, Elodie; Mouton-Faivre, Claudie; Abs, Diane; Bursztejn, Anne-Claire.

Afiliação

Lellig E; Department of Dermatology and Allergology, University Hospital of Nancy, VandÅuvre-lès-Nancy, France.
Mouton-Faivre C; Department of Dermatology and Allergology, University Hospital of Nancy, VandÅuvre-lès-Nancy, France.
Abs D; Department of Dermatology and Allergology, University Hospital of Nancy, VandÅuvre-lès-Nancy, France.
Bursztejn AC; Department of Dermatology and Allergology, University Hospital of Nancy, VandÅuvre-lès-Nancy, France. Electronic address: ac.bursztejn@chru-nancy.fr.

J Allergy Clin Immunol Pract ; 10(7): 1922-1923, 2022 07.

Article em En | MEDLINE | ID: mdl-35470099

Assuntos

COVID-19; Toxidermias; Vacina BNT162; Toxidermias/diagnóstico; Toxidermias/etiologia; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxidermias / COVID-19 Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google